Compare TG Therapeutics Inc (TGTX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? TG Therapeutics Inc trades at $54.84 (market cap $8.16B), while T Rowe Price Group Inc trades at $104.86 (market cap $22.23B). The key difference: T Rowe Price Group Inc is far larger — about 2.7× TG Therapeutics Inc's market cap, and T Rowe Price Group Inc pays a 4.99% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and T Rowe Price Group Inc for 115 Days on average.
| TGTX | TROW | |
|---|---|---|
Market Cap | $8.16B | $22.23B |
Volume | 1,735,121 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $59.06 | $121.68 |
52-Week Low | $26.94 | $86.19 |
Typical Hold Time | 16 Days | 115 Days |
Enterprise Value | $8.37B | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
T. Rowe Price (TROW) trades at $105.47, up 1.35% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 10.46, net income margin of 29.26%, and consistent dividend growth spanning 40 years. Recent earnings beat expectations in Q1 and Q2 2026, while AUM reached $1.90 trillion in August 2026 despite net outflows.
The stock presents value characteristics with attractive valuation multiples and dividend yield near 5%, though technical weakness and analyst caution (63% hold rating) suggest near-term consolidation. Key catalysts include Q3 earnings due soon and the company's expansion into ETF offerings through F/m Investments acquisition, while risks include market-sensitive revenue and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
